絞り込み

17724

広告

「火球」の隕石を発見「すごい音がして怖かった」隕石の起源は (NHK)

先月、広い範囲で目撃された「火球」が燃え尽きずに、隕石(いんせき)として落ちているのを発見した千葉県の女性が取材に応じ、当時の状況について「すごい大きな音がして...

  1. 宇宙飛行士になったような臨場感ある映像…...
  2. 新規コンテンツページ - (2400)
  3. 東京 武蔵村山市の病原体扱う施設 移転先...
  4. 研究環境基盤部会 共同利用・共同研究拠点...

ニュース一覧

Nonbismuth Quadruple (Concomitant) Therapy: Empirical and Tailored Efficacy versus Standard Triple Therapy for Clarithromycin-Susceptible Helicobacter pylori and versus Sequential Therapy for Clarithromycin-Resistant Strains.

著者 Molina-Infante J , Pazos-Pacheco C , Vinagre-Rodriguez G , Perez-Gallardo B , Dueñas-Sadornil C , Hernandez-Alonso M , Gonzalez-Garcia G , Mateos-Rodriguez JM , Fernandez-Bermejo M , Gisbert JP
Helicobacter.2012 Aug ; 17(4):269-76.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

Departments of Gastroenterology Microbiology, Hospital San Pedro de Alcantara, Caceres, Spain Department of Gastroenterology, Hospital Universitario de la Princesa, Instituto de Investigación Sanitaria Princesa (IP) and Centro de Investigación Biomédica e

スターを付ける スターを付ける     (187view , 0users)

Full Text Sources

Medical

Miscellaneous

Background:  Using quadruple clarithromycin-containing regimens for Helicobacter pylori eradication is controversial with high rates of macrolide resistance. Aim:  To evaluate antibiotic resistance rates and the efficacy of empirical and tailored nonbismuth quadruple (concomitant) therapy in a setting with cure rates <80% for triple and sequential therapies. Methods:  209 consecutive naive H. pylori-positive patients without susceptibility testing were empirically treated with 10-day concomitant therapy (proton pump inhibitors (PPI), amoxicillin 1 g, clarithromycin 500 mg, and metronidazole 500 mg; all drugs b.i.d.). Simultaneously, 89 patients with positive H. pylori culture were randomized to receive triple versus concomitant therapy for clarithromycin-susceptible H. pylori, and sequential versus concomitant therapy for clarithromycin-resistant strains. Eradication was confirmed with (13) C-urea breath test or histology 8 weeks after completion of treatment. Results:  Per-protocol (PP) and intention-to-treat eradication rates after empirical concomitant therapy without susceptibility testing were 89% (95%CI:84-93%) and 87% (83-92%). Antibiotic resistance rates were: clarithromycin, 20%; metronidazole, 34%; and both clarithromycin and metronidazole, 10%. Regarding clarithromycin-susceptible H. pylori, concomitant therapy was significantly better than triple therapy by per protocol [92% (82-100%) vs 74% (58-91%), p = 0.05] and by intention to treat [92% (82-100%) vs 70% (57-90%), p = 0.02]. As for antibiotic-resistant strains, eradication rates for concomitant and sequential therapies were 100% (5/5) vs 75% (3/4), for clarithromycin-resistant/metronidazole-susceptible strains and 75% (3/4) vs 60% (3/5) for dual-resistant strains. Conclusions:  Empirical 10-day concomitant therapy achieves good eradication rates, close to 90%, in settings with multiresistant H. pylori strains. Tailored concomitant therapy is significantly superior to triple therapy for clarithromycin-susceptible H. pylori and at least as effective as sequential therapy for resistant strains.
PMID: 22759326 [PubMed - in process]
印刷用ページを開く Endnote用テキストダウンロード